Patents by Inventor Luc Villeneuve
Luc Villeneuve has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9636363Abstract: Methods for treating an infection in a tissue sample are described. Tissue samples that are harvested from a patient may be infected with either bacteria or a virus. A rhodamine compound is mixed with the infected tissue sample to form a mixture. The mixture is then exposed to radiant energy to inhibit or kill the bacteria. The exposed mixture is then transplanted into the patient. The rhodamine compounds may be 2?-(6-dimethylamino-3-dimethylimino-3H-xanthen-9-yl) 4?, 5?-dichloro-benzoic acid methyl ester hydrochloride.Type: GrantFiled: January 28, 2013Date of Patent: May 2, 2017Assignee: Kiadis Pharma Canada Inc.Inventors: Abdelkrim Habi, Denis Gravel, Luc Villeneuve, Hongsheng Su, Marc Vaillancourt
-
Publication number: 20140314720Abstract: Methods for treating an infection in a tissue sample are described. Tissue samples that are harvested from a patient may be infected with either bacteria or a virus. A rhodamine compound is mixed with the infected tissue sample to form a mixture. The mixture is then exposed to radiant energy to inhibit or kill the bacteria. The exposed mixture is then transplanted into the patient. The rhodamine compounds may be 2?-(6-dimethylamino-3-dimethylimino-3H-xanthen-9-yl)4?,5?-dichloro-benzoic acid methyl ester hydrochloride.Type: ApplicationFiled: January 28, 2013Publication date: October 23, 2014Inventors: Abdelkrim Habi, Denis Gravel, Luc Villeneuve, Hongsheng Su, Marc Vaillancourt
-
Patent number: 8802082Abstract: Compositions and methods for reducing or preventing graft-versus-host disease associated with allogeneic stem cell transplantation are described. A method includes harvesting hematopoietic cells from a patient with an immunologic disorder and harvesting hematopoietic cells from a donor. The harvested hemaptopoietic cells from the patient and the donor are mixed ex vivo for a period of time sufficient to activate lymphocytes within the hematopoietic cells harvested from the donor such that an immune reaction occurs and an activated portion and an unactivated portion is produced. A rhodamine B derivative is then added to the mixture of cells and the mixture is irradiated at a suitable wavelength and intensity for the selective destruction and/or inactivation of the activated portion without substantially affecting the unactivated portion or causing systemic toxicity in said patient. The irradiated cells are then infused into the patient.Type: GrantFiled: March 29, 2013Date of Patent: August 12, 2014Assignees: Universite de Montreal, Hopital Maisonneuve-RosemontInventors: Denis-Claude Roy, Martin Guimond, Nestor Molfino, Luc Villeneuve
-
Publication number: 20130089130Abstract: A radio frequency receiver comprising a receiver module, an intermediate frequency (“IF”) module, a synthesizer module and a controller module. The receiver module receives a radio frequency signal and provides a baseband in-phase signal and a baseband quadrature signal, eliminates a sideband of the in-phase and quadrature signals to create a first and a second signal, downconverts the first and second signal to a first and a second IF signal, and selects one of the first or second IF signals. The IF module receives the first or second IF signal, performs analog-to-digital conversion on the first or second IF signal, and demodulates the digitally converted IF signal. The synthesizer module receives a programmable reference signal, downconverts the reference signal to an IF feedback signal, downconverts the reference signal to a baseband feedback signal, provides the IF feedback signal to the IF module, and provides the baseband feedback signal to the receiver module.Type: ApplicationFiled: September 25, 2012Publication date: April 11, 2013Inventors: Ying Shen, Guy Theberge, Richard Bourdeau, Luc Villeneuve, Fabio Concilio, Thanh Nguyen
-
Patent number: 8409564Abstract: The present invention relates to the use of the photoactivable derivatives for the photodynamic treatment for the selective destruction and/or inactivation of immunologically reactive cells without affecting the normal cells and without causing systemic toxicity for the patient, wherein appropriate intracellular levels of said derivatives are achieved and irradiation of a suitable wavelength and intensity is applied.Type: GrantFiled: October 21, 2004Date of Patent: April 2, 2013Assignees: Universite de Montreal, Hopital Maisonneuve-RosemontInventors: Denis-Claude Roy, Martin Guimond, Nestor Molfino, Luc Villeneuve
-
Patent number: 8383672Abstract: Methods for treating a bacterial infection in a tissue sample are described. Tissue samples that are harvested from a patient may be infected with bacteria. A rhodamine compound is mixed with the infected tissue sample to form a mixture. The mixture is then exposed to radiant energy to inhibit or kill the bacteria. The exposed mixture is then transplanted into the patient.Type: GrantFiled: June 9, 2011Date of Patent: February 26, 2013Assignee: Kiadis Pharma Canada Inc.Inventors: Abdelkrim Habi, Denis Gravel, Luc Villeneuve, Hongsheng Su, Marc Vaillancourt
-
Patent number: 8275071Abstract: A radio frequency receiver comprising a receiver module, an intermediate frequency (“IF”) module, a synthesizer module and a controller module. The receiver module receives a radio frequency signal and provides a baseband in-phase signal and a baseband quadrature signal, eliminates a sideband of the in-phase and quadrature signals to create a first and a second signal, downconverts the first and second signal to a first and a second IF signal, and selects one of the first or second IF signals. The IF module receives the first or second IF signal, performs analog-to-digital conversion on the first or second IF signal, and demodulates the digitally converted IF signal. The synthesizer module receives a programmable reference signal, downconverts the reference signal to an IF feedback signal, downconverts the reference signal to a baseband feedback signal, provides the IF feedback signal to the IF module, and provides the baseband feedback signal to the receiver module.Type: GrantFiled: May 17, 2007Date of Patent: September 25, 2012Assignee: Harris Stratex Networks Operating CorporationInventors: Ying Shen, Guy Theberge, Richard Bourdeau, Luc Villeneuve, Fabio Concilio, Thanh Nguyen
-
Publication number: 20120136338Abstract: The present invention provides for methods of treating a cancer patient. In one methods, cancer cells are harvested from a patient. A therapeutic amount of a rhodamine derivative is then added to the harvested cancer cells. The harvested cells and the rhodamine derivative are then irradiated with a suitable wavelength and intensity for the selective killing of the cancer cells. The irradiated cancer cells are then mixed with antigen presenting cells to form a mixture. The mixture of cancer and antigen presenting cells are then injected into the patient. The present invention also provides for methods of inhibiting or treating an immunological disorder, infection, or a cancer in an individual.Type: ApplicationFiled: February 3, 2012Publication date: May 31, 2012Inventors: DENIS CLAUDE ROY, Marc Vaillancourt, Luc Villeneuve
-
Publication number: 20110301573Abstract: Methods for treating a bacterial infection in a tissue sample are described. Tissue samples that are harvested from a patient may be infected with bacteria. A rhodamine compound is mixed with the infected tissue sample to form a mixture. The mixture is then exposed to radiant energy to inhibit or kill the bacteria. The exposed mixture is then transplanted into the patient.Type: ApplicationFiled: June 9, 2011Publication date: December 8, 2011Inventors: Abdelkri Habi, Denis Gravel, Luc Villeneuve, Hongsheng Su, Marc Vaillancourt
-
Publication number: 20110021616Abstract: Methods for treating a bacterial infection in a tissue sample are described. Tissue samples that are harvested from a patient may be infected with bacteria. A rhodmaine compound is mixed with the infected tissue sample to form a mixture. The mixture is then exposed to radiant energy to inhibit or kill the bacteria. The exposed mixture is then transplanted into the patient.Type: ApplicationFiled: May 24, 2010Publication date: January 27, 2011Applicant: KIADIS PHARMA CANADA INC.Inventors: ABDELKRIM HABI, DENIS GRAVEL, LUC VILLENEUVE, HONGSHENG SU, MARC VAILLANCOURT
-
Patent number: 7560574Abstract: Compounds of formula (I) wherein: one of R1, R2, R3, R4 and (R10)n represents halogen and each remaining R1, R2, R3, R4 and R10 group is independently selected from hydrogen, halogen, amino, acylamino, dialkylamino, cycloalkylamino, azacycloalkyl, alkylcycloalkylamino, aroylamino, diarylamino, arylalkylamino, aralkylamino, alkylaralkylamino, arylaralkylamino, hydroxy, alkoxy, aryloxy, aralkyloxy, mercapto, alkylthio, arylthio, aralkylthio, carboxyl, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, cyano, hydroxysulfonyl, amidosulfonyl, dialkylamidosulfonyl, arylalkylamidosulfonyl, formyl, acyl, aroyl, alkyl, alkylene, alkenyl, aryl, aralkyl, vinyl, alkynyl, and corresponding substituted groups; m=0-1; n=1-4, A is nil, O, or NH; R9 is alkylene; -Z is H, amino, dialkylamino, or a trialkylamino salt; X? is an anion; R5, R6, R7 and R8 are independently H or C1-C6 alkyl or R1 in combination with R5 or R6, or R2 in combination with R5 or R6, or R3 in combination wiType: GrantFiled: March 27, 2002Date of Patent: July 14, 2009Assignee: Celmed Biosciences Inc.Inventors: Abdelkrim Habi, Denis Gravel, Luc Villeneuve, Hongsheng Su, Marc Vaillancourt
-
Publication number: 20090176869Abstract: Compounds of formula I: in which one of R1, R2, R3, R4 and (R10)n represents halogen and each of the remaining R1, R2, R3, R4 and R10 groups is independently selected from hydrogen, halogen, amino, acylamino, dialkylamino, cycloalkylamino, azacycloalkyl, alkylcycloalkylamino, aroylamino, diarylamino, arylalkylamino, aralkylamino, alkylaralkylamino, arylaralkylamino, hydroxyl, alkoxy, aryloxy, aralkyloxy, mercapto, alkylthio, arylthio, aralkylthio, carboxyl, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, cyano, hydroxysulfonyl, amidosulfonyl, dialkylamidosulfonyl, arylalkylamido-sulfonyl, formyl, acyl, aroyl, alkyl, alkylene, alkenyl, aryl, aralkyl, vinyl, alkynyl and corresponding substituted groups; m=0-1; n=1-4; A is nil, O or NH; R9 is alkylene, Z is H, amino, dialkylamino or trialkylamino salt; X is an anion; and R5, R6, R7 and R8 are independently selected from H and C1-6 alkyl, or R1 with R5 or R6, or R2 with R5 or R6, or R3 with R7 or R8 represents aType: ApplicationFiled: March 13, 2009Publication date: July 9, 2009Applicant: CELMED BIOSCIENCE INC.Inventors: Abdelkrim Habi, Denis Gravel, Luc Villeneuve, Jean-Pierre Forte, Hongsheng Su, Marc Vaillancourt
-
Publication number: 20080285684Abstract: A radio frequency receiver comprising a receiver module, an intermediate frequency (“IF”) module, a synthesizer module and a controller module. The receiver module receives a radio frequency signal and provides a baseband in-phase signal and a baseband quadrature signal eliminates a sideband of the in-phase and quadrature signals to create a first and a second signal, downconverts the first and second signal to a first and a second IF signal, and selects one of the first or second IF signals. The IF module receives the first or second IF signal, performs analog-to-digital conversion on the first or second IF signal, and demodulates the digitally converted. If signal The synthesizer module receives a programmable reference signal, downconverts the reference signal to an IF feedback signal, downconverts the reference signal to a baseband feedback signal provides the IF feedback signal to the IF module, and provides the baseband feedback signal to the receiver module.Type: ApplicationFiled: May 17, 2007Publication date: November 20, 2008Applicant: Harris Stratex Networks Operating CorporationInventors: Ying Shen, Guy Theberge, Richard Bourdeau, Luc Villeneuve, Fabio Concilio, Thanh Nguyen
-
Publication number: 20070098732Abstract: The present invention relates to the use of PDT-treated cells (whole or fragments thereof) and/or supernatant thereof in the preparation of vaccines for immunoprotection or immunomodulation. More particularly, the use of PDT-treated cells (whole or fragments thereof) and/or supernatant thereof in the preparation of an immunologic compound for prevention, protection, prophylaxis or treatment of an immunological disorder, infection and/or a cancer in an individual, which comprises treatment of the individual cells or components thereof with a photoactivatable molecule selected from the group consisting of compounds I to XVIII, wherein the photoactivatable molecule is activated by a light of appropriate wavelength, thereby activating the photoactivatable molecule and causing prevention, protection, prophylaxis or treatment of the immunological disorder, infection and/or a cancer.Type: ApplicationFiled: December 2, 2004Publication date: May 3, 2007Inventors: Denis Roy, Marc Vaillancourt, Luc Villeneuve
-
Publication number: 20060088507Abstract: The present invention relates to the use of the photoactivable derivatives for the photodynamic treatment for the selective destruction and/or inactivation of immunologically reactive cells without affecting the normal cells and without causing systemic toxicity for the patient, wherein appropriate intracellular levels of said derivatives are achieved and irradiation of a suitable wavelength and intensity is applied.Type: ApplicationFiled: October 21, 2004Publication date: April 27, 2006Applicants: Universite de Montreal, Hopital Maisonneuve-RosemontInventors: Denis-Claude Roy, Martin Guimond, Nestor Molfino, Luc Villeneuve
-
Patent number: 5798523Abstract: An apparatus for irradiating a biological substance with a substantially uniform quantity of radiation energy comprises a radiation-generating device for producing radiation energy, a support structure for receiving the biological substance, and a motorized mechanism for reciprocating the radiation-generating device along a given path whereby the biological substance receives radiation energy from the radiation-generating device at each passage of the radiation-generating device. A series of sensors lie into a given plane and are subjected to radiation energy from the radiation-generating device upon each passage of that radiation-generating device for sensing and measuring the quantity of radiation energy by surface unit passing through the given plane and reaching the biological substance. Finally the radiation-generating device and the motorized mechanism are de-energized when the measured quantity of radiation energy by surface unit has reached a predetermined value.Type: GrantFiled: July 19, 1996Date of Patent: August 25, 1998Assignee: Theratechnologies Inc.Inventors: Luc Villeneuve, Gerard Miller, Robert Bernier, Claude Laurendeau, Prabir Kumar Pal
-
Patent number: 5773460Abstract: The present invention relates to novel photoactivable rhodamine derivatives for enhancing high quantum-yield production and singlet oxygen generation upon irradiation with light while maintaining desirable differential retention of rhodamine between normal and cancer cells. Representative derivatives are2-(4,5-dibromo-6-amino-3-imino-3H-xanthen-9-yl)-benzoic acid methyl ester hydrochloride; 2-(4, 5-dibromo-6-amino-3-imino-3H-xanthen-9-yl)-benzoic acid ethyl ester hydrochloride; 2-(4,5-dibromo-6-amino-3-imino-3H-xanthen-9-yl)-benzoic acid octyl ester hydrochloride; 2-(4,5-dibromo-6-amino-3-imino-3H-xanthen-9-yl)-benzoic acid n-butyl ester hydrochloride; 2-(6-ethyl amino-3-ethyl imino-3H-xanthen-9-yl)-benzoic acid n-butyl ester hydrochloride; and photoactivable derivatives thereof.Type: GrantFiled: July 1, 1996Date of Patent: June 30, 1998Assignee: Universite De MontrealInventors: Louis Gaboury, Luc Villeneuve, Richard Giasson, Tiechao Li, Ajay Kumar Gupta
-
Novel rhodamine derivatives for photodynamic therapy of cancer and in vitro purging of the leukemias
Patent number: 5556992Abstract: The present invention relates to novel photoactivable rhodamine derivatives for enhancing high quantum-yield production and singlet oxygen generation upon irradiation with light while maintaining desirable differential retention of rhodamine between normal and cancer cells, said derivatives are selected from the group consisting of 4,5-dibromorhodamine 123 (2-(4,5-dibromo-6-amino-3-imino-3H-xanthen-9-yl)-benzoic acid methyl ester hydrochloride); 4, 5-dibromorhodamine 123 (2-(4,5-dibromo-6-amino-3-imino-3H-xanthen-9-yl)-benzoic acid ethyl ester hydrochloride); 4, 5-dibromorhodamine 123 (2-(4,5-dibromo-6-amino-3-imino-3H-xanthen-9-yl)-benzoic acid octhyl ester hydrochloride); 4,5-dibromorhodamine 110 n-butyl ester (2-(4,5-dibromo-6-amino-3-imino-3H-xanthen-9-yl)-benzoic acid n-butyl ester hydrochloride); Rhodamine B n-butyl ester (2-(6-ethyl amino-3-ethyl imino-3H-xanthen-9-yl)-benzoic acid n-butyl ester hydrochloride); and photoactivable derivatives thereof; whereby photoactivation of the derivatives induces cType: GrantFiled: September 2, 1994Date of Patent: September 17, 1996Assignee: Universite de MontrealInventors: Louis Gaboury, Luc Villeneuve, Richard Giasson, Tiechao Li, Ajay K. Gupta